Shares of Mesa Laboratories (MLAB) surged 5.2% in pre-market trading on Tuesday, following the company's impressive third-quarter fiscal 2025 results and upbeat outlook.
The life science tools and quality control solutions provider reported better-than-expected earnings of $2.72 per share, surpassing analysts' estimates by a wide margin. Revenue also came in higher at $62.84 million, beating expectations by nearly 7%.
The strong performance was driven by solid growth across all business segments, particularly in the Biopharmaceutical Development and Calibration Solutions divisions. The company's strategic acquisitions, including GKE, also contributed to the revenue growth.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。